Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)
Sponsor: Kali Therapeutics, Inc.
Summary
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
Official title: A Phase 1, Open-Label, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KT502 by Subcutaneous Administration in Adult Participants With Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2026-07
Completion Date
2028-07
Last Updated
2026-05-04
Healthy Volunteers
No
Conditions
Interventions
KT502
KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3
Locations (2)
Kali Therapeutics Trial Site
Bayswater, Victoria, Australia
Kali Therapeutics Trial Site
Auckland, NZ, New Zealand